Anbenitamab  (Synonyms: KN-026)

Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting extracellular domains II and IV of human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathways. Anbenitamab mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγIIIa binding. Ambrinitumab can be used in research for lung cancer, HER2-positive metastatic breast cancer (MBC), gastric cancer, and gastroesophageal junction cancer^[1][2][3][4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Anbenitamab 在 Calu-3 细胞中的最大抑制率为 53.94%，在 NCI-N87 细胞中的最大抑制率为 32.16%^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2064  [NCBI] & 7150  [NCBI]

P04626 & P11387

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.16 kDa

2367012-88-0

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Dongmei Ji, et al. Abstract 3022: Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody. Cancer Res (2020) 80 (16_Supplement): 3022.

  [2]. Jian Zhang, et al. First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study. Clin Cancer Res. 2022 Feb 15;28(4):618-628.  [Content Brief]

  [3]. Wang Z, et al. Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo. MAbs. 2024 Jan-Dec;16(1):2412881.  [Content Brief]

  [4]. Xu J, et al. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. Eur J Cancer. 2023 Jan;178:1-12.  [Content Brief]